Breaking News Instant updates and real-time market news.

ARAV

Aravive

$9.50

-0.06 (-0.63%)

17:14
11/26/19
11/26
17:14
11/26/19
17:14

Aravive offers to sell common stock, no amount given

Piper Jaffray and Cantor Fitzgerald & Co. are acting as joint book runners for the offering.

ARAV Aravive
$9.50

-0.06 (-0.63%)

10/10/19
HCWC
10/10/19
INITIATION
Target $18
HCWC
Buy
Aravive initiated with a Buy rating at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis initiated coverage of Aravive with a Buy rating and $18 price target, stating that he thinks the company's lead asset, AVB-500, could be "compelling" for the treatment of various tumor indications and "a valuable ally in the context of combinatory therapies in multiple lines of treatment." He also thinks the safety and efficacy data reported from its ongoing Phase 1b/2 study opens the possibility of exploring an accelerated path forward with the FDA.
11/20/19
PIPR
11/20/19
NO CHANGE
Target $36
PIPR
Overweight
Aravive price target raised to $36 from $15 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Aravive to $36 from $15 after the company updated data from 31 platinum-resistant ovarian cancer patients receiving AVB-500 plus chemotherapy in an ongoing Phase Ib study. The stock in morning trading is up 72%, or $4.80, to $11.50. Seventeen of 31 patients achieved the minimal efficacious concentration of AVB-500, which significantly correlated to a four-fold increase in progression free survival, Tenthoff tells investors in a research note. High AVB-500 exposure also resulted in an overall response rate of 29% versus 14% for low exposure, adds the analyst. He points out the results exceed the historical three-to-four month median progress free survival and 10%-15% response in this population. Citing the "positive" Phase Ib data, Tenthoff reiterates an Overweight rating on Aravive.
11/20/19
HCWC
11/20/19
NO CHANGE
Target $31
HCWC
Buy
Aravive price target raised to $31 from $18 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Aravive to $31 from $18 and reiterated a Buy rating after the company updated positive data from platinum-resistant ovarian cancer patients receiving AVB-500 plus chemotherapy in an ongoing Phase 1b study, saying results from 31 patients treated with the 10mg/kg dose of AVB-500 in combination with pegylated liposomal doxorubicin or with paclitaxel support and extend the prior observation of efficacy in 28 patients. In a research note to investors, Pantginis says the current results point to positive outcomes at higher doses, and that data on ORR and PFS in these patients are expected in mid-2020.
11/20/19
WEDB
11/20/19
NO CHANGE
Target $28
WEDB
Outperform
Aravive price target raised to $28 from $12 at Wedbush
Wedbush analyst David Nierengarten reiterated an Outperform rating on Aravive and raised his price target on the shares to $28 from $12 following the reporting of "encouraging" AVB-500 dose-escalation data from the Phase 1b/2 trial evaluating the decoy AXL receptor in combination with standard single-agent chemo in 31 pts with platinum-resistant ovarian cancer. Nierengarten said he believes AVB-500's emerging clinical profile in platinum-resistant ovarian cancer and "encouraging" exposure-response relationship continues to support his view of its best-in-class status among AXL pathway inhibitors. As such, the analyst said he would be a buyer of Aravive shares ahead of the preliminary readout from the higher 15 and 20 mg/kg dose groups, which he expects will be positive, that's anticipated in the middle of next year.

TODAY'S FREE FLY STORIES

CONN

Conn's

$20.51

1.08 (5.56%)

07:43
12/10/19
12/10
07:43
12/10/19
07:43
Downgrade
Conn's rating change  »

Conn's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

LULU

Lululemon

$231.08

1.58 (0.69%)

07:42
12/10/19
12/10
07:42
12/10/19
07:42
Recommendations
Lululemon analyst commentary  »

Lululemon price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

GOLD

Barrick Gold

$16.85

-0.045 (-0.27%)

07:41
12/10/19
12/10
07:41
12/10/19
07:41
Hot Stocks
Barrick Gold to sell 90% interest in Massawa project to Teranga for up to $430M »

Barrick Gold announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$62.68

-1.77 (-2.75%)

07:41
12/10/19
12/10
07:41
12/10/19
07:41
Hot Stocks
Sage Therapeutics announces planned progression of SAGE-718 »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$237.33

-4.62 (-1.91%)

07:40
12/10/19
12/10
07:40
12/10/19
07:40
Recommendations
RH analyst commentary  »

RH price target raised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WCC

Wesco

$54.92

-0.32 (-0.58%)

, AXE

Anixter

$88.88

-0.18 (-0.20%)

07:39
12/10/19
12/10
07:39
12/10/19
07:39
Upgrade
Wesco, Anixter rating change  »

Wesco upgraded to Strong…

WCC

Wesco

$54.92

-0.32 (-0.58%)

AXE

Anixter

$88.88

-0.18 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

NFLX

Netflix

$302.48

-4.88 (-1.59%)

07:39
12/10/19
12/10
07:39
12/10/19
07:39
Conference/Events
Netflix management to meet with UBS »

Dinner Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

SGEN

Seattle Genetics

$114.26

-3.26 (-2.77%)

07:38
12/10/19
12/10
07:38
12/10/19
07:38
Initiation
Seattle Genetics initiated  »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

SYBT

S.Y. Bancorp

$41.02

-0.03 (-0.07%)

07:38
12/10/19
12/10
07:38
12/10/19
07:38
Conference/Events
S.Y. Bancorp management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

DG

Dollar General

$154.81

0.075 (0.05%)

07:37
12/10/19
12/10
07:37
12/10/19
07:37
Hot Stocks
Dollar General announces availability of CBD products in select states »

Dollar General announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HROW

Harrow Health

$6.53

0.04 (0.62%)

07:37
12/10/19
12/10
07:37
12/10/19
07:37
Hot Stocks
Harrow Health subsidiary announces outsourcing facility ships to California »

ImprimisRx, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TENB

Tenable Holdings

$24.81

-0.46 (-1.82%)

07:36
12/10/19
12/10
07:36
12/10/19
07:36
Recommendations
Tenable Holdings analyst commentary  »

Tenable Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TROW

T. Rowe Price

$124.48

0.59 (0.48%)

07:35
12/10/19
12/10
07:35
12/10/19
07:35
Hot Stocks
T. Rowe Price reports preliminary AUM $1.18T at November 30 »

Client transfers from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

FTSV

Forty Seven

$30.44

16.04 (111.39%)

07:35
12/10/19
12/10
07:35
12/10/19
07:35
Recommendations
Forty Seven analyst commentary  »

Forty Seven price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$47.34

0.62 (1.33%)

, TPR

Tapestry

$25.80

0.26 (1.02%)

07:35
12/10/19
12/10
07:35
12/10/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

ZS

Zscaler

$47.34

0.62 (1.33%)

TPR

Tapestry

$25.80

0.26 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 16

    Dec

  • 10

    Jan

FRAN

Francesca's

$19.83

1.29 (6.96%)

07:34
12/10/19
12/10
07:34
12/10/19
07:34
Earnings
Francesca's reports Q3 adj. EPS ($1.12) vs. ($2.08) last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

WH

Wyndham Hotels & Resorts

$57.94

-0.1 (-0.17%)

07:34
12/10/19
12/10
07:34
12/10/19
07:34
Conference/Events
Wyndham Hotels & Resorts management to meet with Wolfe Research »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CNST

Constellation Pharmaceuticals

$36.15

-7.95 (-18.03%)

07:33
12/10/19
12/10
07:33
12/10/19
07:33
Recommendations
Constellation Pharmaceuticals analyst commentary  »

Constellation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

AMGN

Amgen

$232.74

-1 (-0.43%)

07:33
12/10/19
12/10
07:33
12/10/19
07:33
Hot Stocks
Amgen says Phase 3 CANDOR study met primary endpoint »

Amgen announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$17.10

-0.59 (-3.34%)

, BMRN

BioMarin

$78.87

-1.03 (-1.29%)

07:32
12/10/19
12/10
07:32
12/10/19
07:32
Hot Stocks
Invitae launches Discover Dysplasias initiative with BioMarin »

Invitae (NVTA) announced…

NVTA

Invitae

$17.10

-0.59 (-3.34%)

BMRN

BioMarin

$78.87

-1.03 (-1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATI

Allegheny Technologies

$23.76

0.1 (0.42%)

, GE

General Electric

$10.99

-0.105 (-0.95%)

07:32
12/10/19
12/10
07:32
12/10/19
07:32
Hot Stocks
Allegheny Technologies extends long-term purchase agreements with GE Aviation »

Allegheny Technologies…

ATI

Allegheny Technologies

$23.76

0.1 (0.42%)

GE

General Electric

$10.99

-0.105 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 29

    Jan

PTON

Peloton

$34.78

2.215 (6.80%)

07:31
12/10/19
12/10
07:31
12/10/19
07:31
Recommendations
Peloton analyst commentary  »

Peloton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VVV

Valvoline

$22.21

-0.17 (-0.76%)

07:31
12/10/19
12/10
07:31
12/10/19
07:31
Conference/Events
Valvoline management to meet with Buckingham »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

PCG

PG&E

$11.05

1.4 (14.51%)

07:30
12/10/19
12/10
07:30
12/10/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

LEG

Leggett & Platt

$52.17

-0.91 (-1.71%)

07:29
12/10/19
12/10
07:29
12/10/19
07:29
Downgrade
Leggett & Platt rating change  »

Leggett & Platt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.